Media

The following information is intended as a resource for journalists only and was factually correct at the time it was issued. For up to date safety information please refer to current consumer medicine information and product information.

For media-related enquiries, please contact

Corporate Communications
Australia and New Zealand
[email protected]

AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act. Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.

2023

November

Inflammatory bowel disease experts call for urgent action to ensure equitable, multidisciplinary care in australia as prevalence continues to rise
Read full media release here.
Read pdf version of the full media release here.

August

New oral treatment listed on the PBS for arthritis of the spine and pelvis
Read full media release here.
Read pdf version of the full media release here.

March

AbbVie celebrates recognition as leader in workplace gender equity
Read full media release here.
Read pdf version of the full media release here.

January

AbbVie announces registration of RINVOQ^® (upadacitinib) for another type of arthritis
Read full media release here.
Read pdf version of the full media release here.

2022

November

AbbVie Australia named on prestigious Best Workplaces for Women list
Read full media release here.
Read pdf version of the full media release here.

October

AbbVie announces leadership changes for Australia
Read full media release here.
Read pdf version of the full media release here.

September

AbbVie welcomes the registration of RINVOQ® (upadacitinib) for adult patients with moderately to severely active ulcerative colitis
Read full media release here.
Read pdf version of the full media release here.

August

AbbVie’s commitment to diversity and inclusion lands them #5 on the Best Workplaces list
Read full media release here.
Read pdf version of the full media release here.

May

AbbVie welcomes the registration of SKYRIZI® (risankizumab) for psoriatic arthritis
Read full media release here.
Read pdf version of the full media release here.

January

RINVOQ® (upadacitinib) Now Listed on the PBS for Australia’s Most Common and Severe Form of Eczema, Atopic Dermatitis
Read full media release here.
Read pdf version of the full media release here.

2021

November

New treatment for an aggressive blood cancer available on the PBS
Read full media release here.
Read pdf version of the full media release here.

October

New treatment for debilitating rheumatic diseases listed on the PBS
Read full media release here.
Read pdf version of the full media release here.

September

VENCLEXTA® (venetoclax) has now received full registration for adult patients with newly diagnosed Acute Myeloid Leukaemia who are ineligible for intensive chemotherapy
Read full media release here.
Read pdf version of the full media release here.

September

AbbVie welcomes registration of RINVOQ® (upadacitinib) for atopic dermatitis
Read full media release here.
Read pdf version of the full media release here.

August

AbbVie reinforces “it’s the people, not the place” in their ninth year of recognition as a Great Place to Work
Read full media release here.
Read pdf version of the full media release here.

May

AbbVie welcomes registration of RINVOQ® (upadacitinib) for two new indications
Read full media release here.
Read pdf version of the full media release here.

March

New option for Australians with certain autoimmune diseases through reimbursement of HUMIRA® (adalimumab) citrate-free formulation
Read full media release here.
Read pdf version of the full media release here.

2020

December

Venclexta (venetoclax) PBS listed as first line therapy for Chronic Lymphocytic Leukaemia (CLL) patients unfit for chemotherapy
Read full media release here.
Read pdf version of the full media release here.

October

AbbVie collaborates with BioCurate to accelerate commercialisation of Australian novel early stage discoveries into new therapeutics and drugs
Read full media release here.
Read pdf version of the full media release here.

September

MAVIRET® is the first PBS listed Hepatitis C treatment available for Australians 12 years and over
Read full media release here.
Read pdf version of the full media release here.

July

New treatment for rheumatoid arthritis, RINVOQ (upadacitinib), became available on the PBS during COVID-19 lockdown
Read full media release here.

July

AbbVie reinvents ‘pharma culture’ and takes Australia’s #2 spot for Best Place to Work
Read full media release here.

May

AbbVie Completes Transformative Acquisition of Allergan
Read full media release here.

March

AbbVie Australia - Local Response to COVID-19
Read here.

January

AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of RINVOQ® (upadacitinib)
Read full media release here.

2019

December

Chris Stemple Appointed General Manager AbbVie ANZ
Read full media release here.

December

New biologic option for severe plaque psoriasis now available on Pharmaceutical Benefits Scheme
Read full media release here.

July

AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of SKYRIZI™ (risankizumab)
Read full media release here.

June

AbbVie ANZ Appoints New Medical Director
Read full media release here.

February

New targeted treatment option for patients with Chronic Lymphocytic Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Read full media release here.

2018

October

AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab
Read full media release here.

August

Eight-week Hepatitis C Treatment on Pharmaceutical Benefits scheme from 1st August 2018
Read full media release here.

April

Announcement: Venclexta PBS Status
Read full media release here.

February

Experts concerned Parksinon’s patients may be missing out on support in the Illawarra
Read full media release here.